相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival
Davide Ciardiello et al.
CLINICAL COLORECTAL CANCER (2022)
Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study
C. Santos Vivas et al.
ANNALS OF ONCOLOGY (2022)
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
J. Pascual et al.
ANNALS OF ONCOLOGY (2022)
Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.
Yoshinori Kagawa et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
Andrea Sartore-Bianchi et al.
NATURE MEDICINE (2022)
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
Stefania Napolitano et al.
FRONTIERS IN ONCOLOGY (2022)
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients
Stefano Mariani et al.
FRONTIERS IN ONCOLOGY (2022)
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09
Akihito Tsuji et al.
TARGETED ONCOLOGY (2021)
Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
Davide Ciardiello et al.
CANCERS (2021)
Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer
Davide Ciardiello et al.
CANCERS (2021)
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients
Roberto Moretto et al.
CLINICAL COLORECTAL CANCER (2021)
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer The Phase 2 Single-Arm Clinical CAVE Trial
Erika Martinelli et al.
JAMA ONCOLOGY (2021)
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives
Nicola Personeni et al.
CANCERS (2021)
Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
E. Martinelli et al.
ANNALS OF ONCOLOGY (2020)
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis
Daniele Rossini et al.
CLINICAL COLORECTAL CANCER (2020)
Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment inKRASwild-type metastatic colorectal cancer: JACCRO CC-08
Toshiki Masuishi et al.
BRITISH JOURNAL OF CANCER (2020)
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper
Arvind Dasari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer
Yu Sunakawa et al.
JCO PRECISION ONCOLOGY (2020)
Is there a role for rechallenge and reintroduction of anti-EGFR plus chemotherapy in later lines of therapy for metastatic colorectal carcinoma? A retrospective analysis
Amanda Karani et al.
ECANCERMEDICALSCIENCE (2020)
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies
Gianluca Mauri et al.
CANCER TREATMENT REVIEWS (2019)
Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial
Yoshihito Ohhara et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Selecting treatment options in refractory metastatic colorectal cancer
Margaret Byrne et al.
ONCOTARGETS AND THERAPY (2019)
Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
Datian Chen et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan ± cetuximab in the EPIC study.
Alberto F. Sobrero et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
C. M. Parseghian et al.
ANNALS OF ONCOLOGY (2019)
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients
K. Shitara et al.
ANNALS OF ONCOLOGY (2019)
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan A Phase 2 Single-Arm Clinical Trial
Chiara Cremolini et al.
JAMA ONCOLOGY (2019)
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer The UNICANCER PRODIGE18 Randomized Clinical Trial
Jaafar Bennouna et al.
JAMA ONCOLOGY (2019)
Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic: Validation of the JAX PlasmaMonitor™ Assay
Bridgette A. Sisson et al.
BIOMARKER INSIGHTS (2019)
Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
John H. Strickler et al.
CANCER DISCOVERY (2018)
RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study
J. B. Bachet et al.
ANNALS OF ONCOLOGY (2018)
Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review
D. Arnold et al.
ANNALS OF ONCOLOGY (2018)
Phase II study of third-line panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who achieved a clinical benefit in response to first-line panitumumab plus chemotherapy
A. Tsuji et al.
ANNALS OF ONCOLOGY (2018)
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial
Jin Li et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study
Hiroaki Tanioka et al.
ONCOLOGY LETTERS (2018)
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses A Phase 2 Randomized Clinical Trial
Clara Montagut et al.
JAMA ONCOLOGY (2018)
481PPhase II study of cetuximab rechallenge in patients with ras wild-type metastatic colorectal cancer: E-rechallenge trial
H Osawa et al.
ANNALS OF ONCOLOGY (2018)
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
S. Siena et al.
ANNALS OF ONCOLOGY (2018)
Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
Richard M. Goldberg et al.
ESMO OPEN (2018)
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
Filippo Pietrantonio et al.
CLINICAL CANCER RESEARCH (2017)
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
Stefano Cascinu et al.
EUROPEAN JOURNAL OF CANCER (2017)
Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
Surajit Pathak et al.
Oncotarget (2017)
P-167Cetuximab rechallenge in metastatic colorectal cancer patients
A. Nogueira et al.
ANNALS OF ONCOLOGY (2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR
Andrea Sartore-Bianchi et al.
CANCER TREATMENT REVIEWS (2016)
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Beth O. van Emburgh et al.
NATURE COMMUNICATIONS (2016)
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives
Julian Holch et al.
VISCERAL MEDICINE (2016)
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
X. Liu et al.
BMC CANCER (2015)
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena et al.
CLINICAL CANCER RESEARCH (2015)
The genomic landscape of response to EGFR blockade in colorectal cancer
Andrea Bertotti et al.
NATURE (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients (vol 21, pg 795, 2015)
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Colorectal Cancer Survival Gains and Novel Treatment Regimens A Systematic Review and Analysis
Irfan Jawed et al.
JAMA ONCOLOGY (2015)
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
Richard B. Lanman et al.
PLOS ONE (2015)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
Sandra Misale et al.
CANCER DISCOVERY (2014)
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies
Claudia Esposito et al.
CANCER BIOLOGY & THERAPY (2013)
Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
Giuseppe Tonini et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer
Alberto Bardelli et al.
CANCER DISCOVERY (2013)
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D. Santini et al.
ANNALS OF ONCOLOGY (2012)
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Sandra Misale et al.
NATURE (2012)
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Luis A. Diaz et al.
NATURE (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
Tim Forshew et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations
D Dressman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
